Novartis AG ADR (NVS) Shares Outstanding 2006–TTM

Name: Novartis AG ADR (NVS) shares outstanding history 2006-TTM
Creator: TickerBase

DATA UPDATED 2026-07-19

Novartis AG ADR annual shares outstanding for fiscal TTM was 1,916 million shares, a decrease of 2.0% from 1,955 million shares in fiscal 2025. All figures are reported results from public filings — no estimates or projections.

NVS Annual Shares Outstanding

Shares Outstanding (annual)	TTM → 2026-03-31	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31	2012-12-31	2011-12-31	2010-12-31	2009-12-31	2008-12-31	2007-12-31	2006-12-31
Shares Outstanding (M)	1,916M	1,955M	2,035M	2,092M	2,197M	2,260M	2,296M	2,319M	2,344M	2,371M	2,400M	2,438M	2,470M	2,479M	2,445M	2,413M	2,301M	2,277M	2,284M	2,329M	2,360M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

NVS Quarterly Shares Outstanding

Shares Outstanding (quarterly)	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30
Shares Outstanding (M)	1,916M	1,929M	1,940M	1,960M	1,979M	2,004M	2,027M	2,046M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

More NVS metrics: Revenue · Gross Profit · Operating Income · Net Income · EPS · EBITDA · Free Cash Flow

All NVS financial statements → Interactive NVS charts →

About TickerBase · Data methodology & sources

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.